Royalty Report: Drugs, Cancer, cell therapy – Collection: 295067


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • cell therapy
  • Drug Discovery
  • Radiation
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 295067

License Grant
The Company entered into a global license and collaboration agreement with German Licensor to develop and commercialize a PTRT and imaging agent targeting FAP.

This drug discovery collaboration agreement is to identify up to three additional, undisclosed targets, and any resulting product candidates.

License Property
The three additional targets will be in addition to the previous target – peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha.
Field of Use
The targets are for peptide-targeted radionuclide therapy.

Targeted radionuclide therapy (also called molecular radiotherapy) involves a radioactive drug called a radiopharmaceutical that targets cancer cells. Radiopharmaceuticals typically consist of a radioactive atom (also known as a radionuclide) combined with a cell-targeting molecule that seeks and destroys cancer cells.

IPSCIO Record ID: 1351

License Grant
Licensor, a non-profit cancer treatment and research institution, hereby grants to Licensee an exclusive license in the field under Licensor Patents and Licensor Know-How to develop, use, make, have made, market, offer to sell, sell and import for sale Licensed Products in the Territory with the right to sublicense.
Licensee shall have the right to grant sublicenses under the license to employ Affiliates and Third Parties.
License Property
Licensee and Licensor wish to cooperate in optimizing the development and commercialization of targeted Ac-225 and/or Bi-213 as therapeutics by API.

SK979 – Targeted alpha particle therapy with DOTA-based complexes of Ac225 – US Provisional application number 60/232,909.
SK933 – Liposome encapsulation of Ac225 – US Provisional application number 60/212,186.
SK352 – Alpha emitting constructs and used thereof – US Provisional application number 60/086,772.
SK712 – Bi-213 Generator and used thereof – US Provisional application number 60/079,902.

Field of Use
Licensed Products shall mean a product, that is covered by a valid claim of an Licensor patent or which incorporates and utilizes Licensor  know-how, prepared for therapeutic use comprising the radionuclide Ac-225 or Bi-213, and one or more targeting, delivery, attachment or carrier moieties including but not limited to monoclonal or other antibodies, antibody fragments or antibody derivatives, receptor ligands, proteins, peptides, liposomes, small molecules, or chemical chelators.

The field shall mean all therapeutic use of Licensed Products in humans and animals.

IPSCIO Record ID: 263763

License Grant
For the Compound and Product, the Licensor grants the Swiss Licensee an exclusive, sublicensable license in the Field in the Territory under Licensor Patent Rights, Licensor Know-How, Licensor Product Trademarks and Companion Diagnostic Trademarks to make, have made, use, offer to sell, sell, import and otherwise Develop and Commercialize Compound and Product.

Licensor grants to Licensee, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable,  license in the Territory under such issued letters patent for Licensee to develop, make, have made, use, sell, offer for sale or import Compounds and Products in the Territory.

For the Covenants/Companion Diagnostic,  Licensor grants a non-exclusive license, with the right to grant sublicenses, under Licensor Patent Rights, Licensor Know-How, and Companion Diagnostic Trademarks to  market and promote the Companion Diagnostic in the Field in the Territory for use in connection with the Product and use the Companion Diagnostic in any way necessary or reasonably useful in order for Licensee to exercise the license granted by Licensor.

This agreement is to develop and commercialize a novel investigational therapeutic candidate vintafolide (EC145).

License Property
Vintafolide is a late-stage cancer drug candidate.

Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine monohydrazide (DAVLBH).

Etarfolatide is a folate-targeted molecular imaging agent that is being developed as a noninvasive method to identify tumors that over-express folate receptors.

Product(s) means any pharmaceutical or biological preparation.

Field of Use
Vintafolide is currently being evaluated in a Phase Ill clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC}; both studies are also using investigational companion diagnostic agent, etarfolatide (EC20).

Vintafolide is designed to preferentially target the chemotherapy agent to fast growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian, NSCLC, breast, colon and kidney.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.